Hospira Symbiq Infusion System Vulnerability
view advisory published 2015-03-26
This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov
01
describes (1)
Related CVEs.
| ID | severity | exploitable | ||
|---|---|---|---|---|
| CVE-2015-3965US | high8.8 | — | ||
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call… | ||||
02
references
External citations — patches, advisories, analysis.
- ICS Advisory ICSA-15-174-01 JSONself
- Recommended Practicesexternal
- ICS Advisory ICSA-15-174-01 - Web Versionself
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
- Recommended Practicesexternal
03
remediations (1)
- MitigationSymbiq Infusion System
Hospira has provided compensating measures to help mitigate risks associated with this vulnerability. As previously announced by Hospira in 2013, the Symbiq Infusion System would be retired on May 31, 2015, and will be fully removed from the market by December 2015.
scry
Advisories like this name the exposed products attackers go after on your perimeter. See what is exposed on your perimeter with a free passive scan.
Free scan